AbbVie Inc. ABBV
286.00 USD -2.84 (-0.98%)
At closeNov 3, 2026, 5:56 PM EST
285.92 -0.08 -0.03%
After hours · Nov 3, 5:56 PM ET
284.71 Day range 291.32
190.75 52-week range 298.74
- YTD
- +25.17%
- 1 year
- +34.93%
Analyst view
Consensus: buy
Buy
Price target (mean) 306.42 +7.1% upside
Now 286.00
- Target (low)
- 237.00
- Target (mean)
- 306.42
- Target (high)
- 350.00
Ratings (0m) 29 23 buy · 5 hold · 1 sell
- Strong buy7
- Buy16
- Hold5
- Sell0
- Strong sell1
Recommendation trend
- This month 29
- 1 month ago 29
- 2 months ago 30
- 3 months ago 31
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 3.89 | 3.84 – 4.01 | 2.71 | +43.4% | 18.41B | +10.8% | 19 |
| Next quarter | 3.44 | 3.30 – 3.90 | 2.65 | +29.6% | 16.42B | +9.5% | 9 |
| Current year | 13.99 | 13.90 – 14.13 | 10.00 | +39.9% | 67.81B | +10.9% | 26 |
| Next year | 16.18 | 15.17 – 17.23 | 13.99 | +15.7% | 73.85B | +8.9% | 29 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | UBS | Maintained | Neutral | Neutral |
| Nov 2, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Nov 2, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Nov 2, 2026 | Guggenheim | Maintained | Buy | Buy |
| Nov 2, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Nov 2, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Nov 2, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 2, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Oct 23, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Oct 21, 2026 | Barclays | Maintained | Overweight | Overweight |
| Oct 13, 2026 | RBC Capital | Reiterated | Outperform | Outperform |
| Oct 9, 2026 | UBS | Maintained | Neutral | Neutral |
| Oct 9, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Oct 8, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 8, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Oct 7, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 6, 2026 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| Sep 10, 2026 | HSBC | Maintained | Buy | Buy |
| Aug 20, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 17, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 13, 2026 | Wolfe Research | Upgrade | Peer Perform | Outperform |
| Aug 11, 2026 | BNP Paribas | Maintained | Neutral | Neutral |
| Aug 10, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Aug 6, 2026 | Berenberg | Maintained | Buy | Buy |
| Aug 5, 2026 | Erste Group | Upgrade | Hold | Buy |
| Aug 4, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 3, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 3, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Aug 3, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jul 31, 2026 | TD Cowen | Maintained | Buy | Buy |
